Insider · CIK 0001867033
Tyler Zeronda
Files at YARW (VYNE Therapeutics Inc.). First filing -, latest -.
In brief
Tyler Zeronda files SEC Form 4 as CFO and director at YARW (VYNE Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Tyler Zeronda has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +185,798 | $0.00 | $0 | 185,798 | Jul 29, 2026 |
| Jul 23, 2026 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -22,516 | $0.90 | $20k | 74,918 | Jul 24, 2026 |
| Jun 30, 2026 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -3,464 | $0.65 | $2,254 | 97,434 | Jul 2, 2026 |
| Mar 31, 2026 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -4,007 | $0.60 | $2,394 | 99,788 | Apr 2, 2026 |
| Dec 31, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -7,858 | $0.58 | $4,558 | 103,795 | Jan 5, 2026 |
| Sep 30, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -3,420 | $0.34 | $1,146 | 111,653 | Oct 2, 2025 |
| Jun 30, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -3,420 | $1.65 | $5,643 | 115,073 | Jul 2, 2025 |
| Mar 31, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -8,399 | $1.58 | $13k | 118,493 | Apr 2, 2025 |
| Dec 13, 2023 | YARW VYNE Therapeutics Inc. | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 69,430 | Dec 15, 2023 |
| Dec 13, 2023 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +62,500 | $0.00 | $0 | 62,500 | Dec 15, 2023 |
Questions about Tyler Zeronda
Answered from the filings on this page, as of the latest one.
Is Tyler Zeronda buying or selling?
Tyler Zeronda has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Tyler Zeronda's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Tyler Zeronda has 0.
Where does Tyler Zeronda file Form 4?
Tyler Zeronda has filed Form 4 at YARW (VYNE Therapeutics Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.